In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs

KP167 is a novel hypoxia‐activated prodrug (HAP), targeting cancer cells via DNA intercalating and alkylating properties. The single agent and radiosensitizing efficacy of KP167 and its parental comparator, AQ4N, were evaluated in 2D and 3D cultures of luminal and triple negative breast cancer (TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiyappa‐Maudsley, Radhika, Elsalem, Lina, Ibrahim, Ali I. M., Pors, Klaus, Martin, Stewart G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357624/
https://www.ncbi.nlm.nih.gov/pubmed/35841287
http://dx.doi.org/10.1111/jcmm.17486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357624/
https://www.ncbi.nlm.nih.gov/pubmed/35841287
http://dx.doi.org/10.1111/jcmm.17486

Ejemplares similares